Emulsifier-restrictive diet effective in alleviating symptoms in CD

Emulsifier restriction was a safe and effective therapy among participants with mild-to-moderate Crohn’s disease (CD) in the ADDapt trial. The diet was associated with a reduction in symptoms and inflammatory markers.

The ADDapt trial (NCT04046913) randomised 154 participants with mild-to-moderate CD who showed signs of active disease 1:1 to a low emulsifier diet or an emulsifier-containing diet [1]. Dr Aaron Bancil (King’s College London, UK) and co-investigators applied a re-supplementation methodology, meaning that both groups received the low emulsifier diet while providing extra emulsifier-containing snacks to participants in the control arm. The primary endpoint was the Crohn’s Disease Activity Index (CDAI) response at week 8.

In the low emulsifier group, 49.4% of the participants achieved a CDAI ≥70 response, compared with 30.7% in the control group, representing a significant difference (RR 3.1; 95% CI 1.5–6.6; P=0.003). Moreover, CDAI remission rates (59.5% vs 46.7%; RR 2.1; 95% CI 1.0–4.4; P=0.042) and faecal calprotectin reduction (>50%) rates (21% vs 13%; RR 2.9; 95% CI 1.1–8.0; P=0.039) favoured the active arm over the control arm.

“Emulsifier restriction appears to be a viable way to reduce symptoms and inflammation in patients with mild-to-moderate CD who display objective signs of inflammation,” concluded Dr Bancil.

1. Bancil A. Emulsifier restriction is an effective therapy for active Crohn’s disease: the ADDapt trial: a multi-centre, randomised, double-blind, placebo-controlled, re-supplementation trial in 154 patients. DOP097, 20th Congress of ECCO, 19–22 February 2025, Berlin, Germany.

Copyright ©2025 Medicom Medical Publishers



Posted on 8 April 2025